Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Gesine Bug, MD, Carsten Müller-Tidow, MD, Richard F Schlenk, MD, Alwin Krämer, MD, Michael Lübbert, MD, PhD, Utz Krug, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Pilar Garin-Chesa, MD, PhD, Oliver G Ottmann, MD, Hartmut Döhner, MD

Blood (2011) 118 (21): 1549.

https://doi.org/10.1182/blood.V118.21.1549.1549

Published: 2011

Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD

Blood (2010) 116 (21): 3316.

https://doi.org/10.1182/blood.V116.21.3316.3316

Published: 2010

Journal Articles

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Vivek L. Patel, MS, Matthieu Mahévas, MD, Roberto Stasi, MD, Susanna Cunningham-Rundles, PhD, Bertrand Godeau, MD, Soo Y. Lee, BS, Julie Kanter, MD, Ellis J. Neufeld, MD, PhD, Tillmann Taube, MD, Ugo Ramenghi, MD, Shalini Shenoy, MD, Mary J. Ward, PhD, Nino Mihatov, BS, Vinay L. Patel, BS, Philippe Bierling, MD, Nichola Cooper, MD, James B. Bussel, MD

Blood (2010) 116 (21): 72.

https://doi.org/10.1182/blood.V116.21.72.72

Published: 2010

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Specific Inhibition of BCR-ABL Gene Expression in Acute Lymphoblastic Leukemia by Catalytic DNAzymes.

Tillmann Taube, MD, Shabnam Shalapour, Georg J. Seifert, MD, Madlen Pfau, Guenter Henze, MD, PhD, Karlheinz Seeger, MD, PhD

Blood (2005) 106 (11): 148.

https://doi.org/10.1182/blood.V106.11.148.148

Published: 2005

NARROW

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Specific Inhibition of BCR-ABL Gene Expression in Acute Lymphoblastic Leukemia by Catalytic DNAzymes.

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Specific Inhibition of BCR-ABL Gene Expression in Acute Lymphoblastic Leukemia by Catalytic DNAzymes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only